PRF Technologies Ltd. Annual Report: A Plain-English Guide

I have put together this guide to help you understand how PRF Technologies Ltd. (formerly PainReform) performed this year. My goal is to turn complex filings into clear information so you can decide if this company belongs in your portfolio.

1. What does this company do?

PRF Technologies is currently balancing two very different worlds: medical development and solar technology.

• Medical Pipeline: They are developing PRF-110, a long-lasting pain reliever for surgery, and OcuRing, a drug delivery system for the eye. Both are in early stages and require significant cash to fund clinical trials.
• Solar Technology: Through its acquisition of DeepSolar, the company is developing high-efficiency solar energy systems. This marks a shift from a pure biotech firm to a diversified technology company.

2. The "Reverse Split" Rollercoaster

You may have noticed significant stock price volatility. The company has used several "reverse stock splits" to keep its share price above the $1.00 minimum required to stay listed on the Nasdaq.

• The Timeline: They performed a 1-for-10 split in 2023, a 1-for-6 in September 2024, a 1-for-4 in November 2024, and a 1-for-5 split in February 2026.
• What this means for you: These splits do not change the company’s total value, but they are a red flag. They show that the share price has struggled to meet exchange requirements. It indicates significant financial pressure, as the market has consistently lowered the stock price after each round of fundraising.

3. Financial Health: The "Burning Cash" Phase

The company is not yet profitable. It reported a loss of about $8.4 million for the last fiscal year. Research and development costs make up 65% of their total budget.

• Funding: The company holds about $1.2 million in cash. With a monthly spending rate of $400,000 to $500,000, they have only 3 to 6 months of cash left before they need more money.
• Dilution: To stay afloat, the company frequently issues new shares. In the last year, the number of shares increased by 45%. This reduces your ownership percentage and lowers the potential earnings for each share you own.

4. Major Risks

• Going Concern: Auditors have warned that there is substantial doubt about the company’s ability to stay in business over the next 12 months without new funding.
• Development Risk: The company’s value depends entirely on its technology. If their medical trials fail or the solar business fails to land contracts, they have no other way to make money.
• Volatility: Frequent share issuances and reverse splits make this a high-risk, speculative stock. It is prone to extreme price swings, often dropping whenever the company announces it needs more cash.

5. Future Outlook

The company aims to finish its medical trials and commercialize its solar assets. This is a high-stakes "build" phase. You are not buying a stable, profitable company; you are betting on their research and management’s ability to find funding without issuing more shares. Success depends on hitting a major milestone within the next six months.

Final Thought for Your Portfolio: If you are considering an investment here, ask yourself if you are comfortable with a "binary" outcome—where the company either hits a major breakthrough or faces a severe liquidity crisis. Given the current cash runway and the history of dilution, this stock is best suited for those with a very high risk tolerance who are closely monitoring the company's next funding announcement.